In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …

Simple Summary CA125 has been the most promising biomarker for screening ovarian
cancer; however, it still does not have an acceptable accuracy in population-based …

Background In advanced oestrogen receptor-positive, HER2-negative breast cancer,
acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones …

The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …

Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …

Background Although most patients with epithelial ovarian cancer respond to frontline
platinum-based chemotherapy, around 70% will relapse within 3 years. The phase 3 …

Financial Disclosure Ernst Lengyel disclosed that money was paid to his institution from
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …

Among a litany of malignancies affecting the female reproductive tract, that of the ovary is the
most frequently fatal. Moreover, while the steady pace of scientific discovery has fuelled …

Background Treatment of newly diagnosed advanced-stage ovarian cancer typically
involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to …

Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …